ACUR — Acura Pharmaceuticals Share Price
Last trade - 00:00- $0.66m
- $0.80m
- $1.56m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.71 | ||
| Price to Tang. Book | 3.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -196.81% | ||
| Return on Equity | n/a | ||
| Operating Margin | -43.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.97 | 0.41 | 2.66 | 3.57 | 1.56 | n/a | n/a | -18.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Directors
- Robert Jones CEO (62)
- Peter Clemens CFO (68)
- Robert Seiser VPR (57)
- Albert Brzeczko VPR (64)
- James Emigh VPR (65)
- George Ross IND (79)
- William Skelly IND (70)
- Immanuel Thangaraj IND (49)
- Bruce Wesson IND (78)
- Last Annual
- December 31st, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- April 10th, 1935
- Public Since
- September 12th, 2000
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 66,001,783
- Address
- 616 N North Ct Ste 120, PALATINE, 60067-8121
- Web
- http://acurapharm.com/
- Phone
- +1 8477057709
- Contact
- Peter Clemens
- Auditors
- BDO USA, LLP
Upcoming Events for ACUR
Similar to ACUR
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 19:00 UTC, shares in Acura Pharmaceuticals are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Acura Pharmaceuticals last closed at $0.01 and the price had moved by -80% over the past 365 days. In terms of relative price strength the Acura Pharmaceuticals share price has underperformed the S&P500 Index by -82.35% over the past year.
There is no consensus recommendation for this security.
Acura Pharmaceuticals does not currently pay a dividend.
Acura Pharmaceuticals does not currently pay a dividend.
Acura Pharmaceuticals does not currently pay a dividend.
To buy shares in Acura Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Acura Pharmaceuticals had a market capitalisation of $0.66m.
Here are the trading details for Acura Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ACUR
Based on an overall assessment of its quality, value and momentum Acura Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acura Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +2773.58%.
As of the last closing price of $0.01, shares in Acura Pharmaceuticals were trading -93.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Acura Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Acura Pharmaceuticals' management team is headed by:
- Robert Jones - CEO
- Peter Clemens - CFO
- Robert Seiser - VPR
- Albert Brzeczko - VPR
- James Emigh - VPR
- George Ross - IND
- William Skelly - IND
- Immanuel Thangaraj - IND
- Bruce Wesson - IND